• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Enveric Biosciences Inc.

    11/13/24 11:18:03 AM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ENVB alert in real time by email
    SC 13G/A 1 ea022071804-13ga3intra_enver.htm AMENDMENT NO. 3 TO SCHEDULE 13G

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 3)*

     

    Enveric Biosciences, Inc.

     

    (Name of Issuer)

     

    Common Stock, $0.01 par value per share

     

    (Title of Class of Securities)

     

    29405E208

    (CUSIP Number)

     

    September 30, 2024

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    a.☐ Rule 13d-1(b)
    b.☒ Rule 13d-1(c)
    c.☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    Page 1 of 6

     

     

    CUSIP No. 29405E208
     
     
     

     

    1. Names of Reporting Persons.
       
      Mitchell P. Kopin
       
     
     
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
       
      (a)   ☐
      (b)   ☐
     
     

     

    3. SEC Use Only
       
       
    4. Citizenship or Place of Organization     United States of America
       

     

    Number of
    Shares Beneficially
    Owned by Each
    Reporting Person
    With:
    5.  Sole Voting Power 0
       
       
    6.  Shared Voting Power

    290,000

       
       
    7.  Sole Dispositive Power 0
       
       
    8.  Shared Dispositive Power

    290,000

     

       
    9. Aggregate Amount Beneficially Owned by Each Reporting Person    290,000 (see Item 4)
       
       
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)   ☐
       
       
    11. Percent of Class Represented by Amount in Row (9)  3.1% (see Item 4)
       
       
    12. Type of Reporting Person (See Instructions)
       
      IN; HC

     

    Page 2 of 6

     

     

    CUSIP No. 29405E208
     
     
     

     

    1. Names of Reporting Persons.
       
      Daniel B. Asher
       
     
     
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
       
      (a)   ☐
      (b)   ☐
     
     

     

    3. SEC Use Only
       
       
    4. Citizenship or Place of Organization     United States of America
       

     

    Number of
    Shares Beneficially
    Owned by Each
    Reporting Person
    With:
    5.  Sole Voting Power 0
       
       
    6.  Shared Voting Power

    290,000

       
       
    7.  Sole Dispositive Power 0
       
       
    8.  Shared Dispositive Power

    290,000

     

       
    9. Aggregate Amount Beneficially Owned by Each Reporting Person    290,000 (see Item 4)
       
       
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)   ☐
       
       
    11. Percent of Class Represented by Amount in Row (9)  3.1% (see Item 4)
       
       
    12. Type of Reporting Person (See Instructions)
       
      IN; HC

     

    Page 3 of 6

     

     

    CUSIP No. 29405E208
     
     
     

     

    1. Names of Reporting Persons.
       
      Intracoastal Capital LLC
       
     
     
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
       
      (a)   ☐
      (b)   ☐
     
     

     

    3. SEC Use Only
       
       
    4. Citizenship or Place of Organization     Delaware
       

     

    Number of
    Shares Beneficially
    Owned by Each
    Reporting Person
    With:
    5.  Sole Voting Power 0
       
       
    6.  Shared Voting Power

    290,000

       
       
    7.  Sole Dispositive Power 0
       
       
    8.  Shared Dispositive Power

    290,000

     

       
    9. Aggregate Amount Beneficially Owned by Each Reporting Person    290,000 (see Item 4)
       
       
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)   ☐
       
       
    11. Percent of Class Represented by Amount in Row (9)  3.1% (see Item 4)
       
       
    12. Type of Reporting Person (See Instructions)
       
      OO

     

    Page 4 of 6

     

     

    This Amendment No. 3 is being filed jointly by the Reporting Persons and amends the Schedule 13G initially filed by the Reporting Persons with the Securities and Exchange Commission (the “SEC”) on August 1, 2022, as amended by Amendment No. 1 thereto filed by the Reporting Persons with the SEC on February 8, 2023, and as amended by Amendment No. 2 thereto filed by the Reporting Persons with the SEC on February 6, 2024 (the “Schedule 13G”).

     

    Except as set forth below, all Items of the Schedule 13G remain unchanged. All capitalized terms not otherwise defined herein shall have the meanings ascribed to such terms in the Schedule 13G.

     

    Item 4. Ownership.

     

    (a) and (b):

     

    As of the close of business on September 30, 2024, each of the Reporting Persons may have been deemed to have beneficial ownership of 290,000 shares of Common Stock issuable upon exercise of a warrant held by Intracoastal (the “Intracoastal Warrant”), and all such shares of Common Stock in the aggregate represent beneficial ownership of approximately 3.1% of the Common Stock, based on (i) 8,919,920 shares of Common Stock as of August 30, 2024, as reported by the Issuer and (2) 290,000 shares of Common Stock issuable upon exercise of the Intracoastal Warrant.

     

    (c) Number of shares as to which each Reporting Person has:

     

    (i) Sole power to vote or to direct the vote:     0    .

     

    (ii) Shared power to vote or to direct the vote:     290,000    .

     

    (iii) Sole power to dispose or to direct the disposition of     0    .

     

    (iv) Shared power to dispose or to direct the disposition of     290,000    .

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following þ.

     

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

     

    Page 5 of 6

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: November 13, 2024

     

      /s/ Mitchell P. Kopin
      Mitchell P. Kopin
       
      /s/ Daniel B. Asher
      Daniel B. Asher

     

      Intracoastal Capital LLC
         
      By: /s/ Mitchell P. Kopin
        Mitchell P. Kopin, Manager

     

     

    Page 6 of 6

     

    Get the next $ENVB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ENVB

    DatePrice TargetRatingAnalyst
    3/8/2022$7.00 → $0.20Buy → Hold
    Aegis Capital
    7/8/2021$7.00Buy
    Aegis Capital
    6/28/2021$6.00Buy
    Maxim Group
    More analyst ratings

    $ENVB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Enveric Biosciences Announces Participation in 2025 BIO International Convention

      Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of psychiatric and neurological disorders, today announced that the company is participating in the BIO International Convention being held June 16-19, 2025, in Boston, Massachusetts. During the conference, CEO and Director of Enveric, Joseph Tucker, Ph.D., will conduct one-on-one meetings with registered investors and potential partners, showcasing the company's business and development strategy, recent corporate achievements, and anticipated milestones. About Enveric Biosciences Enveric Bioscience

      6/16/25 10:46:00 AM ET
      $ENVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Enveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens Targeting Psychiatric Disorders

      Patent-protected aminated tryptamine derivatives strengthen Enveric's leadership in next-generation mental health treatments Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application covering compositions of matter and methods of use for a novel class of aminated tryptamine derivatives. The patented compounds were designed through Enveric's proprietary discovery platform and represent a first-in-class approach to non-h

      6/10/25 9:03:00 AM ET
      $ENVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Enveric Biosciences Announces Issuance of U.S. Patent Covering a Novel Family of Molecules Including Melatonin Receptor-Targeting Compounds

      New Intellectual Property Unlocks Potential for Sleep and CNS Therapeutics Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of psychiatric and neurological disorders, today announced the issuance of a new U.S. patent (USPTO Number 12,187,679). The patent strengthens Enveric's intellectual property portfolio and covers a structurally diverse class of novel molecules with potential therapeutic applications in the treatment of sleep and central nervous system (CNS) disorders. The newly granted patent, titled, "Hydroxylated Psilocybin Derivatives and Me

      6/3/25 9:00:00 AM ET
      $ENVB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ENVB
    SEC Filings

    See more
    • Enveric Biosciences Inc. filed SEC Form 8-K: Financial Statements and Exhibits

      8-K - Enveric Biosciences, Inc. (0000890821) (Filer)

      6/3/25 4:30:18 PM ET
      $ENVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Enveric Biosciences Inc.

      10-Q - Enveric Biosciences, Inc. (0000890821) (Filer)

      5/14/25 4:59:36 PM ET
      $ENVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Enveric Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Enveric Biosciences, Inc. (0000890821) (Filer)

      5/14/25 4:15:30 PM ET
      $ENVB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ENVB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Pasqualone Frank bought $2,140 worth of shares (1,000 units at $2.14)

      4 - Enveric Biosciences, Inc. (0000890821) (Issuer)

      9/19/23 5:34:00 PM ET
      $ENVB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ENVB
    Financials

    Live finance-specific insights

    See more
    • Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023

      Product Development Highlights: Selected neuroplastogen lead candidate EB-003, a potential first-in-class therapeutic option for addressing difficult-to-treat mental health disorders by promoting neuroplasticity without inducing hallucinations. Started IND-enabling preclinical activities for EB-002 and completed important repeat-dose toxicology studies, genotoxicity studies, and key cardiac, respiratory, and CNS safety pharmacology studies. Corporate and Business Development Highlights: Signed three non-binding term sheets with an undisclosed biotechnology company to pursue the out-licensing of three classes of compounds from the Company's extensive portfolio of assets. Signe

      3/26/24 7:00:00 AM ET
      $ENVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Enveric Biosciences Reports First Quarter 2023 Financial Results and Operational Highlights

      Announced cost reduction plan resulting in approximately 40% to 55% decrease in expenses and extension of financial runway into Q1 2024 Continued to advance pipeline of small molecule therapeutics for the treatment of mental health disorders, including EB-373 for the treatment of anxiety disorder and EVM301 Series Announced termination of proposed spin-off of cannabinoid clinical development pipeline to publicly traded company; Enveric now engaging with strategic advisors to identify and pursue alternative value-creating opportunities for cannabinoid assets Enveric Biosciences, Inc. (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of

      5/15/23 9:25:00 AM ET
      $ENVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Enveric Biosciences Announces Confidential Submission of Registration Statement for the Spin-off of its Cannabinoid Business to Shareholders

      The proposed spin-off would create two separate and distinct biotechnology companies, one developing next-generation psychedelic-inspired treatments and the other developing innovative cannabinoid treatments Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders, today announced the confidential submission of a Form S-1 draft registration statement with the U.S. Securities and Exchange Commission (‘SEC') for the spin-off its cannabinoid clinical development pipeline to a wholly-owned subsidiary, Akos Biosciences, Inc. (‘Akos'),

      11/28/22 7:30:00 AM ET
      $ENVB
      Biotechnology: Pharmaceutical Preparations
      Health Care